HealthMore in Health→
Study links Medicare insulin cap to lower costs and better access
Key Takeaways
- A study suggests Medicare patients spent significantly less on insulin after the $35 cap began in 2023.
- The report says more patients appeared to adhere to treatment in the policy’s first year.
- The findings point to insulin affordability as a driver of real-world access.
- The cap could become an important test case in broader drug-pricing debates.
DE
DT Editorial Team··via endpoints.news